Aug 29, 2018

Farmak JSC to invest $10 million in construction of production facilities in Uzbekistan

The Chairman of the Supervisory Board of Farmak JSC and the Ambassador of Uzbekistan to Ukraine agreed on the construction of a new pharmaceutical plant in Uzbekistan.
Farmak JSC plans to build a production site in the Republic of Uzbekistan. During 15 years of successful work in the Republic of Uzbekistan, Farmak JSC became one of the leaders in this region, ranking 4th on the pharmaceutical market of Uzbekistan in terms of sales among corporations, and earned credibility among doctors and population of the republic. The product portfolio marketed by the company in Uzbekistan comprises more than 120 drug products, many of them being socially significant.

“Farmak’s portfolio includes over 200 drug names, 15–20 new products being launched annually. Our company exports the drug products to more than 20 countries of the world, in particular the CIS and the EU, such as Poland, Slovakia, and Germany. The share of export in the company’s total sales is over 25%. Farmak’s strategic goal is to expand its export potential. In order to develop exports, Farmak is considering an investment project worth up to $10 million aimed at localizing production in the Republic of Uzbekistan, launching in-bulk production with gradual transition to full-cycle production, developing more technologically advanced products, in particular, radiopaque and biotechnological. We are ready to bring our positive experience in the development of the pharmaceutical industry in Uzbekistan to provide the population with high-quality medicines”, said Filya Zhebrovska, Chairman of the Supervisory Board of Farmak JSC.

“Farmak’s new production facility will expand the range of drug products manufactured in Uzbekistan, reducing the dependence on imported production and creating a basis for further expansion of the pharmaceutical cluster”, stressed Alisher Abdualiev, Extraordinary and Plenipotentiary Ambassador of the Republic of Uzbekistan to Ukraine.

Back to the News